Sanofi And Regeneron Initiate 400-Patient Coronavirus Trial With Kevzara
The Phase II/III trial will begin enrolling patients in the US immediately, with Regeneron taking the lead in US development and Sanofi leading ex-US trials.
You may also be interested in...
Sanofi/Regeneron Refocus Kevzara COVID-19 Trial On Critical Patients, Showing Value Of A Proper Trial
A Phase III trial testing Kevzara in hospitalized COVID-19 patients will continue only with the high dose in more advanced critical patients after the low-dose was unsuccessful.
Six of seven mid-sized companies enjoyed valuation increases over the first quarter, with four firms up by 7.5% or more. Some are benefiting from direct involvement in addressing the COVID-19 pandemic.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.